Comparative Kinetics of Acetyl- and Butyryl-Cholinesterase Inhibition by Green Tea Catechins|Relevance to the Symptomatic Treatment of Alzheimer's Disease

被引:43
|
作者
Okello, Edward J. [1 ]
Mather, Joshua [2 ]
机构
[1] Fac Med Sci, Populat Hlth Sci Inst, Human Nutr Res Ctr, Leech Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[2] Newcastle Univ, Fac Med Sci, Sch Biomed Nutr & Sport Sci, Catherine Cookson Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
关键词
Alzheimer's; cholinesterase inhibitors; catechins; flavan-3-ols; acetylcholine; neurodegeneration; COGNITIVE FUNCTION; BUTYRYLCHOLINESTERASE; GALANTAMINE; POLYPHENOLS; ACID;
D O I
10.3390/nu12041090
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Alzheimer's disease (AD) is characterised by the apoptosis of cholinergic neurons and the consequent attenuation of acetylcholine mediated neurotransmission, resulting in neurodegeneration. Acetyl-cholinesterase (AChE) and butyryl-cholinesterase (BuChE) are attractive therapeutic targets in the treatment of AD since inhibition of these enzymes can be used to restore synaptic concentrations of acetylcholine. Whilst inhibitors for these enzymes such as galantamine and rivastigmine have been approved for use, none are able to halt the progression of AD and are responsible for the production of troublesome side-effects. Efficacious cholinesterase inhibitors have been isolated from natural plant-based compounds with many demonstrating additional benefits beyond cholinesterase inhibition, such as antioxidation and anti-inflammation, which are key parts of AD pathology. In this study, five natural flavan-3-ol (catechin) compounds: ((-)-epicatechin (EC), catechin, (-)-epicatechin-3-gallate (ECG),) (-)-epigallocatechin (EGC), (-)-epigallocatechin-3-gallate (EGCG), isolated from green tea, were screened for their cholinesterase inhibitory activity using the Ellman assay. The kinetics of inhibition was determined using reciprocal Lineweaver-Burk plots. EGCG was the only compound found to produce statistically significant, competitive inhibition, of both AChE (p < 0.01) and BuChE (p < 0.01) with IC50 values of 0.0148 mu mol/mL and 0.0251 mu mol/mL respectively. These results, combined with previously identified antioxidative and anti-inflammatory properties, highlight the potential use of EGCG in the treatment of AD, provided it can be delivered to cholinergic neurons in therapeutic concentrations. Further testing of EGCG in vivo is recommended to fully characterise the pharmacokinetic properties, optimal method of administration and efficacy of this novel plant-based compound.
引用
收藏
页数:14
相关论文
共 33 条
  • [1] Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit
    Giacobini, E
    Spiegel, R
    Enz, A
    Veroff, AE
    Cutler, NR
    JOURNAL OF NEURAL TRANSMISSION, 2002, 109 (7-8) : 1053 - 1065
  • [2] Acetyl- and butyryl-cholinesterase inhibition by rivastigmine in cerebrospinal fluid of patients with Alzheimer's disease correlates with cognitive benefit
    Giacobini, E
    Spiegel, R
    Enz, A
    Sramek, J
    Cutler, N
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S73 - S73
  • [3] Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit
    E. Giacobini
    R. Spiegel
    A. Enz
    A. E. Veroff
    N. R. Cutler
    Journal of Neural Transmission, 2002, 109 : 1053 - 1065
  • [4] Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer's drugs targeting acetyl- and butyryl-cholinesterase
    Nachon, Florian
    Carletti, Eugenie
    Ronco, Cyril
    Trovaslet, Marie
    Nicolet, Yvain
    Jean, Ludovic
    Renard, Pierre-Yves
    BIOCHEMICAL JOURNAL, 2013, 453 : 393 - 399
  • [5] A new cholinesterase inhibitor in the symptomatic treatment of Alzheimer's disease
    Solignac, M
    PRESSE MEDICALE, 1998, 27 (33): : 1711 - 1711
  • [6] Kinetics and computational study of butyrylcholinesterase inhibition by methylrosmarinate: relevance to Alzheimer?s disease treatment
    Uzairu, Sani Muhammad
    Tijani, Yahaya
    Gadaka, Madu Adamu
    Modu, Babagana
    Watafua, Miriam
    Ahmad, Hadiza Ali
    Zakariya, Umar Abdullahi
    Ibrahim, Aminu
    Daja, Aliyu
    Zanna, Hassan
    Sallau, Abdullahi Balarabe
    HELIYON, 2022, 8 (09)
  • [7] Regulation of Bace1 Mrna Expression in Alzheimer'S Disease by Green Tea Catechins and Black Tea Theaflavins
    Geiser, Ryan J.
    Chastain, Shelby E.
    Moss, Melissa A.
    BIOPHYSICAL JOURNAL, 2017, 112 (03) : 362A - 362A
  • [8] Selectivity of cholinesterase inhibition - Clinical implications for the treatment of Alzheimer's disease
    Weinstock, M
    CNS DRUGS, 1999, 12 (04) : 307 - 323
  • [9] Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease
    Rockwood, K
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2004, 75 (05): : 677 - 685
  • [10] Memantine augments the effects of cholinesterase inhibition in the treatment of Alzheimer's disease
    Lopez, Oscar L.
    Becker, James T.
    Wahed, Abdus S.
    Saxton, Judith
    Sweet, Robert A.
    Wolk, David
    Munk, William
    DeKosky, Steven T.
    NEUROLOGY, 2008, 70 (11) : A96 - A96